HealthCare Global Enterprises Limited
HCG · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹463.14. Low-confidence estimate — limited data.
Piotroski F-score 6/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%1.9%
- ✕Low debt (D/E < 0.5)1.23x
- ✕Positive free cash flow
- ✓Revenue growth > 10%12%
- ✕Earnings growing-71%
- ✕Net margin ≥ 10%0.5%
- ✕Current ratio > 1.51.12
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✕Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✕Altman Z in safe zoneZ 2.77
- ✕Piotroski ≥ 76/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Analyst views
Key fundamentals
SWOT snapshot
Weaknesses
- •Low return on equity (1.9%).
- •High debt relative to equity.
- •Price below its 200-day moving average (downtrend).
Threats
- •Earnings contracting year on year.
- •Rich valuation versus sector peers.
About HealthCare Global Enterprises Limited
HealthCare Global Enterprises Limited provides medical and healthcare services in India and internationally. The company offers cancer diagnostics services, including genomics and molecular diagnostics, digital PET, preventive oncology, physical examination, laboratory tests, home health services, digital pathology, and CTC detection; treatment services, such as medical oncology and haemato-oncology, radiation and surgical oncology, molecular imaging and theranostics, chemoth
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.